Location: Remote. Candidate to be located in the US and near a major airport.
Variable Comp Plan: $120,000.00
Position Overview: The Business Development Director will be responsible for driving B2B growth in xenograft biomaterials, with a focus on fresh tissue, fixed tissue, and collagen-based solutions across key clinical segments including Spine, Sports & Orthopedics, Cardiac, and Plastic & Reconstructive surgery. This role requires deep expertise in xenograft processing, applications, and value propositions within a CDMO environment. The ideal candidate will have a proven track record in business development, particularly within the CDMO space, and a passion for deeply understanding their clients' business and advancing medical technologies.
Key Responsibilities:
• Prospect strategic targets with a focus on companies developing products utilizing xenograft biomaterials (fresh tissue, fixed tissue, and collagen), identifying opportunities aligned with our processing and manufacturing capabilities.
• Develop Key Account Strategies aligned to clients' xenograft sourcing, processing, and commercialization needs, positioning Evergen as a strategic CDMO partner.
• Build and maintain strong relationships with existing and potential clients, ensuring a deep understanding of their requirements and internal processes.
• Orchestrate cross-functional collaboration (R&D, regulatory, and manufacturing) to develop and deliver customized xenograft-based solutions.
• Translate xenograft platform capabilities (e.g., decellularization, fixation, collagen processing) into customer-specific value propositions.
• Identify and shape opportunities where xenograft materials can replace or outperform alternative biomaterials, driving differentiation for customers.
• Lead negotiations and close deals, ensuring favorable terms for the company and high levels of client satisfaction.
• Monitor market trends and competitor activities to identify opportunities for growth and differentiation.
• Prepare for and represent the company at industry conferences, trade shows, and other networking events to promote our capabilities and expand our client base.
• Prepare and present regular reports on business development activities, pipeline status, and sales performance to senior management.
• Leverage CRM tools to maintain documentation of account planning, prospects, and pipeline development.
Qualifications:
• Bachelor's degree in Business Administration, Marketing, or a related field; advanced degree preferred.
• Minimum of 4 years of experience in business development, sales, or a related role within the medical device industry, including at least 2 years within a medical device CDMO environment.
• Deep understanding of xenograft biomaterials, including fresh tissue, fixed tissue, and collagen (fibrillar, solubilized, or formulated), and their applications in medical devices.
• Experience working with xenograft sourcing, processing, or manufacturing (e.g., decellularization, sterilization, or collagen processing).
• Proven track record of achieving sales targets and driving revenue growth.
• Excellent communication, negotiation, and interpersonal skills.
• Ability to work collaboratively with cross-functional teams and manage multiple projects simultaneously.
• Strategic thinker with strong analytical and problem-solving skills.
• Willingness to travel as needed to meet with clients and attend industry events.
Preferred Qualifications:
• Experience with xenograft-based product development or commercialization within a CDMO or OEM environment.
• Familiarity with regulatory and quality considerations specific to xenograft biomaterials.
• Established network of contacts within the medical device industry.
• Clinical expertise in focus market segments: Spine, Sports and Orthopedics, Cardiac, or Plastic and Reconstructive Surgery.
Why Join Us:
• Opportunity to shape and scale a leading xenograft CDMO platform across fresh tissue, fixed tissue, and collagen biomaterials.
• Collaborative and innovative work environment.
• Competitive salary and benefits package.
• Chance to make a significant impact on patient outcomes through advanced biomaterial solutions.
Evergen is committed to creating an inclusive environment where diverse perspectives drive innovation and success.
About Our Ownership
Montagu Private Equity acquired RTI Surgical in 2020 and continues to support Evergen's transformation and long-term growth strategy.
#LI-Remote
